Clinical outcome from oxaliplatin treatment in stage II/III colon cancer according to intrinsic subtypes: Secondary analysis of NSABP C-07/NRG oncology randomized clinical trial

JAMA Oncology

Volumn 2, Issue 9, 2016, Pages 1162-1169

  Song, Nan ^a   Pogue Geile, Katherine L ^a   Gavin, Patrick G ^a   Yothers, Greg ^b,c   Kim, S Rim ^a   Johnson, Nicole L ^a   Lipchik, Corey ^a   Allegra, Carmen J ^a,d   Petrelli, Nicholas J ^a,e   O'Connell, Michael J ^a   Wolmark, Norman ^a,f   Paik, Soonmyung ^a,g  

^a NSABP Foundation Inc   (United States)

^b NRG Oncology ^*  (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e HELEN F GRAHAM CANCER CENTER   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

^g Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; FLUOROURACIL; FOLINIC ACID; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21;

ALGORITHM; CANCER STAGING; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GOBLET CELL; HUMAN; INFLAMMATION; INTESTINE CELL; MALE; MISMATCH REPAIR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; ENTEROCYTES; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GOBLET CELLS; GTP PHOSPHOHYDROLASES; HUMANS; INFLAMMATION; LEUCOVORIN; MALE; MEMBRANE PROTEINS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85010858470     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.2314     Document Type: Conference Paper

References (14)

1. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
2. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-2204.
3. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39 (1):128-135.
4. Yothers G, O'Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. 2013;31(36):4512-4519.
5. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18(23):6531-6541.
6. De Sousa E Melo F,Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5): 614-618.
7. Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619-625.
8. Marisa L, de Reyniés A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5): e1001453.
9. Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134(3):552-562.
10. Sadanandam A,Wang X, de Sousa E Melo F, et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle. 2014;13(3):353-357.
11. Guinney J, Dienstmann R,Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
12. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101 (21):1446-1452.
13. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99(10):6567-6572.
14. Calon A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47 (4):320-329.